South America Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Cancer Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, and Other Cancer Types), Therapeutic Class, Pharmacologic Class, Diagnostics and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
CAGR: 6.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Kidney cancer is a disease that starts in the kidneys. It happens when healthy cells in one or both kidneys grow out of control and form a tumor. Renal cell carcinoma is the most common type of kidney cancer found in adults.

In South America, the cases of kidney cancer are on the rise. This has resulted in increasing demand for kidney therapeutics and diagnostics. Currently, there are various treatment options available and many drugs are in pipeline too, which is expected to drive the kidney cancer therapeutics and diagnostics market during the forecast period. 

In addition, rising investments in research by various government bodies and the development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors. Hence all these factors are expected to help the growth of kidney cancer and therapeutics market in South America.

Scope of the report

As per the scope of the report, kidney cancer is a type of cancer which starts in kidney cells. The kidney cancer therapeutics and diagnostics involves therapy and diagnostics methods that are used for the treatment of renal cancer. The drugs are used for the treatment of various type of kidney cancers.

By Cancer Type
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Other Cancer Types
By Therapeutic Class
Targeted Therapy
By Pharmacologic Class
Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
By Diagnostics
Intravenous Pyelogram
CT Scan
Other Diagnostics
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Application in Renal Cell Carcinoma is expected to Dominate the Market

Renal cell carcinoma is the most common type of adult kidney cancer, making up about 85% of diagnoses. This type of cancer develops in the proximal renal tubules that make up the kidney’s filtration system. There are thousands of these tiny filtration units in each kidney.

In South America, the prevalence of kidney cancer is expected to rise as per the estimates by the International Agency for Research on Cancer 2018 data. As renal cell carcinoma is most common type of cancer, the demand for its therapeutics and diagnostics is expected to rise as well. In addition, there are also other factors that are driving the market that includes growing awareness among people about cancer, the increased diagnostic rates, rising geriatric population, and rising incidence of renal cancer.


Competitive Landscape

South America is a developing region. Although the healthcare system in many countries in the region are not highly developed, these countries are spending more each year in their healthcare system. This has encouraged many global companies to enter the market and as a result, many global players in the patient monitoring market are present in the region. These factors have made the region very competitive.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Number of Kidney Cancer Case

      2. 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Treatment

      2. 4.3.2 Low Success Rate in Clinical Trials for Cancer Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Cancer Type

      1. 5.1.1 Renal Cell Carcinoma

      2. 5.1.2 Clear Cell Renal Cell Carcinoma

      3. 5.1.3 Papillary Renal Cell Carcinoma

      4. 5.1.4 Other Cancer Types

    2. 5.2 By Therapeutic Class

      1. 5.2.1 Targeted Therapy

      2. 5.2.2 Immunotherapy

    3. 5.3 By Pharmacologic Class

      1. 5.3.1 Angiogenesis Inhibitors

      2. 5.3.2 Monoclonal Antibodies

      3. 5.3.3 mTOR Inhibitors

      4. 5.3.4 Others

    4. 5.4 By Diagnostics

      1. 5.4.1 Biopsy

      2. 5.4.2 Intravenous Pyelogram

      3. 5.4.3 CT Scan

      4. 5.4.4 Ultrasound

      5. 5.4.5 Other Diagnostics

    5. 5.5 Geography

      1. 5.5.1 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bayer AG

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 Eisai

      6. 6.1.6 Exelixis

      7. 6.1.7 F. Hoffmann-La Roche

      8. 6.1.8 GlaxoSmithKline PLC

      9. 6.1.9 Novartis International AG

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The South America Kidney Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The South America Kidney Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 6.5% over the next 5 years.

Eisai, Bristol Myers Squibb Company, Exelixis , Novartis International AG , Bayer AG are the major companies operating in South America Kidney Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!